NEXT Oncology at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

NEXT Oncology brings 3 presentations to ENA 2026 in Barcelona. Its posters cover first-in-human trials of new cancer drugs and the biology of KRAS-mutant tumours. They report first results for IPH4502, an anti-Nectin-4 ADC, and the design of a phase 1/2 study of SAR449336, an oral non-covalent pan-KRAS inhibitor.

Organization	ENA 2026 Attendance
NEXT Oncology San Antonio, Texas
nextoncology.com Cancer centres & hospitals Network of phase 1 cancer clinical trial sites in the US, Spain and other countries.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates First Results from a First-in-Human Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502, an anti-Nectin-4 ADC, as a Single Agent in Advanced Solid Tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Lineage- and allele-specific coupling of KRAS alterations with NF-kB inflammatory pathway activity in solid tumours Biomarkers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Novel clinical trial design A First-in-Human Phase 1/2 Study of SAR449336, an Oral Non-Covalent Pan-KRAS Inhibitor, in Patients With Advanced KRAS-Mutant Solid Tumors (Trial in Progress) Early clinical

Organization

ENA 2026 Attendance

NEXT Oncology

San Antonio, Texas

nextoncology.com

Cancer centres & hospitals

Network of phase 1 cancer clinical trial sites in the US, Spain and other countries.

Poster

Wed Nov 18
12–1:30pm
3:50–4:15pm
5:45–7pm

Part of Poster session: Antibody-drug conjugates

First Results from a First-in-Human Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502, an anti-Nectin-4 ADC, as a Single Agent in Advanced Solid Tumors

ADCs & radioligands